A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Public ClinicalTrials.gov record NCT03322566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT03322566
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 233 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- Epacadostat Drug
- Platinum-based chemotherapy Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 9, 2018 (Actual)
- Primary completion
- Dec 13, 2018 (Actual)
- Completion
- Oct 16, 2020 (Actual)
- Last update posted
- Jan 24, 2022
2018 – 2020
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, PC | Daphne | Alabama | 36526 | — |
| Western Regional Medical Center, Inc. | Goodyear | Arizona | 85338 | — |
| Arizona Oncology Associates PC- HOPE | Tucson | Arizona | 85704 | — |
| Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Florida Cancer Specialists (South Region) | Fort Myers | Florida | 33901-8101 | — |
| Florida Cancer Specialists (North Region) | St. Petersburg | Florida | 33705 | — |
| PPG-Oncology | Fort Wayne | Indiana | 46845 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| MMCORC | Saint Louis Park | Minnesota | 55416 | — |
| St. Vincent Healthcare Frontier Cancer Center | Billings | Montana | 59102 | — |
| New York Oncology Hematology P.C | Albany | New York | 12208 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Southwestern Regional Medical Center, Inc. | Tulsa | Oklahoma | 74133 | — |
| St. Luke's Hospital - Anderson Campus | Easton | Pennsylvania | 18045 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Tennessee Oncology, PLLC/The Sarah Cannon Research Institute | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology, PLLC/The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Denton South | Denton | Texas | 76210 | — |
| Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care | Blacksburg | Virginia | 24060 | — |
| Emily Couric Clinical Cancer Center | Charlottesville | Virginia | 22908 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03322566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 24, 2022 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03322566 live on ClinicalTrials.gov.